Analysts Are Bullish on Top Healthcare Stocks: Dr Reddy’s Laboratories (RDY), Dexcom (DXCM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dr Reddy’s Laboratories (RDYResearch Report) and Dexcom (DXCMResearch Report) with bullish sentiments.

Dr Reddy’s Laboratories (RDY)

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories, with a price target of $70.00. The company’s shares closed last Wednesday at $55.19.

According to TipRanks.com, Prasad is a 2-star analyst with an average return of 0.3% and a 40.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Amneal Pharmaceuticals, and Jazz Pharmaceuticals.

Dr Reddy’s Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $67.00.

See the top stocks recommended by analysts >>

Dexcom (DXCM)

BTIG analyst Marie Thibault reiterated a Buy rating on Dexcom today and set a price target of $134.00. The company’s shares closed last Wednesday at $117.26, close to its 52-week high of $126.44.

According to TipRanks.com, Thibault is a 3-star analyst with an average return of 2.7% and a 36.4% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Edwards Lifesciences, and Senseonics Holdings.

Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $140.38.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RDY: